Answers are grounded in this paper and cite their sources.
Background/Objectives: We aimed to develop an integrated B-mode ultrasound framework for hepatic steatosis detection and fibrosis assessment in patients with suspected metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: This multicenter study prospectively included 734 participants with 2485 ultrasound images from eight centers (April 2023–November 2025). A Global Attention Mechanism-enhanced Cross-Attention Multi-Scale Vision Transformer was used to derive a steatosis signature in Dataset A (Centers 1–3, n = 245), with external testing in Datasets B (Centers 4–5, n = 294) and C (Centers 6–8, n = 195). The signature was then integrated with liver elasticity and clinical and laboratory variables to develop a fibrosis prediction model in Dataset B, with external testing in Dataset C. Results: The steatosis signature achieved AUROCs of 0.887 (95% CI, 0.831–0.938) and 0.968 (95% CI, 0.932–0.994) in Datasets B and C, respectively, significantly outperforming the hepatic steatosis index, fatty liver index, and the junior radiologist (AUROC range: 0.728–0.794; all p < 0.05), while performing comparably to the senior radiologist (AUROC range: 0.864–0.932). The fibrosis model achieved an AUROC of 0.849 (95% CI, 0.762–0.916) in Dataset C and significantly outperformed elasticity, fibrosis-4 index, aspartate aminotransferase-to-platelet ratio index, and nonalcoholic fatty liver disease fibrosis score (AUROC range: 0.431–0.697; all p < 0.05). For F0 versus F1, the model also achieved an AUROC of 0.841 (95% CI, 0.745–0.922), significantly outperforming all comparators (all p < 0.05). Conclusions: This integrated framework provides a noninvasive approach for steatosis case-finding and early fibrosis risk stratification in patients with suspected MASLD.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: